

SARS-CoV-2 vaccine Alpha and Delta variant breakthrough infections are rare and mild, but happen relative early after vaccination

Jelissa Katharina Peter^{1,*}, Fanny Wegner^{2,4,5,*}, Severin Gsponer^{1,*}, Fabrice Helfenstein³, Tim Roloff^{2,4,5}, Rahel Tarnutzer¹, Kerstin Grosheintz¹, Moritz Back¹, Carla Schaubhut¹, Sabina Wagner¹, Helena Seth-Smith^{2,4,5}, Patrick Scotton⁶, Maurice Redondo⁷, Christiane Beckmann⁷, Tanja Stadler⁸, Andrea Salzmann⁷, Henriette Kurth⁷, Karoline Leuzinger^{9,10}, Stefano Bassetti¹¹, Roland Binggisser¹², Martin Siegemund¹³, Maja Weisser¹⁴, Manuel Battegay¹⁴, Sarah Tschudin Sutter¹⁴, Aitana Lebrand¹⁵, Hans H. Hirsch^{7,10,14}, Simon Fuchs¹, Adrian Egli^{2,4,+}

1 Health Services for the Canton of Basel-City, 4001 Basel, Switzerland

2 Applied Microbiology Research, Department of Biomedicine, University of Basel, 4056 Basel, Switzerland;

3 Clinical Trial Unit, University Hospital Basel, 4031 Basel, Switzerland

4 Division of Clinical Bacteriology and Mycology, University Hospital Basel, 4031 Basel, Switzerland;

5 SIB Swiss Institute of Bioinformatics, 4053-4056 Basel, Switzerland

6 Corona Vaccination Centre for the Canton of Basel-City, 4058 Basel, Switzerland

7 Viollier AG, Allschwil, Switzerland

8 Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland

9 Clinical Virology, University Hospital Basel, 4031 Basel, Switzerland

10 Transplantation & Clinical Virology, Department of Biomedicine, University of Basel, 4056 Basel, Switzerland;

11 Internal Medicine, University Hospital Basel, 4031 Basel, Switzerland

12 Emergency Medicine, University Hospital Basel, 4031 Basel, Switzerland

13 Intensive Care Medicine, University Hospital Basel, 4031 Basel, Switzerland

14 Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel, 4031 Basel

15 SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland

*authors equally contributed to the work

+ Correspondence:

Prof. Adrian Egli, MD PhD

Clinical Bacteriology and Mycology

Petersgraben 4

4031 Basel, Switzerland

Email: adrian.egli@usb.ch

Abstract (474)

Introduction: COVID-19 vaccines significantly reduce SARS-CoV-2 (SCoV2)-related hospitalization and mortality in randomized controlled clinical trials, as well as in real-world effectiveness against different circulating SCoV2-lineages. However, some vaccine recipients show breakthrough infection and it remains unknown, which host and viral factors contribute to this risk and how many resulted in severe outcomes. Our aim was to identify demographic and clinical risk factors for SCoV2 breakthrough infections and severe disease in fully vaccinated individuals and to compare patient characteristics in breakthrough infections caused by SCoV2 Alpha or Delta variant.

Methods: We conducted an exploratory retrospective case-control study from 28th of December to 25th of October 2021 dominated by the Delta SCoV2 variant. All cases of infection had to be reported by law to the local health authorities. Vaccine recipients' data was anonymously available from the national Vaccination Monitoring Data Lake and the main local vaccine center. We compared anonymized patients' characteristics of breakthrough infection (n=492) to two overlapping control groups including all vaccine recipients from the Canton of Basel-City (group 1 n=126'586 and group 2 n=109'382). We also compared patients with breakthrough infection caused by the Alpha to Delta variant. We used different multivariate generalized linear models (GLM).

Results: We found only 492/126'586 (0.39%) vaccine recipients with a breakthrough infection after vaccination during the 10 months observational period. Most cases were asymptomatic or mild (478/492 97.2%) and only very few required hospitalization (14/492, 2.8%). The time to a positive SCoV2 test shows that most breakthrough infections occurred between a few days to about 170 days after full vaccination, with a median of 78 days (interquartile range, IQR 47-124 days). Factors associated with a lower odds for breakthrough infection were: age (OR 0.987, 95%CI 0.983-0.992), previous COVID-19 infection prior to vaccination (OR 0.296, 95%CI 0.117-0.606), and (self-declared) serious side-effects from previous vaccines (OR 0.289, 95%CI 0.033-1.035). Factors associated with a higher odds for breakthrough infection were: vaccination with the Pfizer/BioNTech vaccine (OR 1.459, 95%CI 1.238-1.612), chronic disease as vaccine indication (OR 2.109, 95%CI 1.692-2.620), and healthcare workers (OR 1.404, 95%CI 1.042-1.860). We did not observe a significantly increased risk for immunosuppressed patients (OR 1.248, 95% CI 0.806-1.849).

Conclusions: Our study shows that breakthrough infections are rare and show mild illness, but that it occurs early after vaccination with more than 50% of cases within 70 to 80 days post-full vaccination. This clearly implies that boost vaccination should be much earlier initiated compared to the currently communicated 180-day threshold. This has important implications especially for risk groups associated with more frequent breakthrough infections such as healthcare workers, and people in high-risk care facilities. Due to changes in the epidemiological dynamic with new variants emerging, continuous monitoring of breakthrough infections is helpful to provide evidence on booster vaccines and patient groups at risk for potential complications.

Introduction

The COVID-19 vaccines induce SARS-CoV-2 (SCoV2)-specific neutralizing antibodies in most vaccine recipients¹⁻⁴ and have shown significant efficacy to reduce COVID-19 related hospitalization and mortality in randomized controlled clinical trials⁵⁻⁷, as well as in real-world effectiveness against different circulating SCoV2 variants⁸⁻¹⁰. However, some vaccine recipients show breakthrough infection either shortly or longer after vaccination^{5,11-13}. It is not yet fully understood, which factors contribute to lower vaccine effectiveness^{14,15} and how to best identify them for a more personalized vaccination and booster strategy. In short-term breakthrough infections, potential reasons include IgA deficiency, immunosuppressive drugs e.g., after organ transplantation¹⁶⁻¹⁸, or immunosenescence¹⁹. In long-term breakthrough infections, most likely SARS-CoV-2 specific neutralizing antibodies titers slowly decrease over time and fall below a certain threshold, which results in an increasing risk of a breakthrough infection²⁰. For this reason, additional third or even fourth vaccine boosters have become clinical practice in many countries by which neutralization titers can be elevated. The World Health Organisation (WHO) recently published an interim statement on booster doses, stating that additional vaccination at standard doses or boosters at reduced doses should be firmly evidence-driven and targeted to the population groups in greatest need²¹.

Beside important host related factors, viral evolution may also contribute to the risk of breakthrough infections, as observed during previous influenza seasons²². Constantly emerging new SCoV2 variants may reduce vaccine efficacy and effectiveness by modulating the viral spike (S)-protein in the receptor binding domain (RBD)^{23,24}, which is critical for binding to the angiotensin converting enzyme (ACE)-2 receptor on the host cell²⁵⁻²⁷. Since the beginning of the SCoV2 pandemic, certain mutations in the viral S-protein have been retained and spread globally, whereby Delta variant (B.1.617.2) has been rapidly displacing most of the other circulating viral variants in Europe. It has been shown that the efficiency to neutralize the Delta variant is lower compared to wild type or Alpha variants. Two-times vaccinated individuals showed a 2.5-fold (Pfizer/BioNtech, Moderna and Janssen vaccine) reduction in neutralization titres against the Delta virus compared to an ancestral G614 S pseudo-virus²⁸ and a 3-fold (Pfizer/BioNtech) and 6-fold (AstraZeneca) reduction in neutralization titres against the Alpha variant²⁴. The rapid molecular epidemiological adaptation and recent introduction of the Delta and Omicron SCoV2 variants makes it more difficult to conclusively define risk factors for breakthrough infection^{29,30}. Recent data shows that the new Omicron variant may show a 40-fold reduction to be neutralized in double dose vaccinated people³¹.

Currently, there are two key questions of high importance for public health decision making regarding vaccination and booster application. Firstly, what are possible demographic and clinical risk factors for SCoV2 breakthrough infections in fully vaccinated individuals? Knowledge would allow us to make general recommendations and prioritize third dose applications. Second, do patient characteristics differ in breakthrough infections caused by SCoV2 Alpha or Delta variant? The answer could help to link viral- and host-factors risk assessments and learn for the emerging Omicron variant.

Since the beginning of the Swiss COVID-19 vaccination campaign in December 2020, for which only uses licensed vaccines from Moderna or Pfizer/BioNTech, we have documented all breakthrough infections of the Canton of Basel-City, including those occurring in persons having received other vaccines licensed in other countries such as AstraZeneca and Janssen. We noted an increasing number of breakthrough infections in fall 2021. Therefore,

we conducted an exploratory retrospective case-control study and aimed to identify factors potentially associated with breakthrough infections in fully vaccinated people. We use a fully anonymized dataset of more than 120'000 fully vaccinated residents of the Canton of Basel-City, who received two doses of the licensed SCoV2 vaccines. We then investigated potential differences in breakthrough infections with either the Alpha or the Delta SCoV2 variants.

Methods

Ethics. The study has been approved by the local ethical committee (EKNZ 2020-00769 and 2021-00774). The data protection office of the Canton of Basel-City also evaluated and approved the study. We received fully anonymized data with minimal demographic information such as age, gender, and self-reported data to conduct the study. For cases of breakthrough infections, we had minimal clinical information available based on the mandatory reporting system and contact tracing information. This data was also anonymized and different teams in data acquisition and analysis were involved. No identification of single individuals is possible.

Setting. The Canton of Basel-City has three municipalities with a total population of 201'386 people (June 2021) and is the most densely populated Swiss canton (5'433/km²) with a population density comparable to Madrid (5'481/km²), London (5'701/km²), and Boston (5'397/km²)³²⁻³⁵. The City of Basel itself is inhabited by 86% of the canton's population. The first COVID-19 vaccine in the Canton of Basel-City was administered on the 28th of December 2020, only 20 days after the launch of the global vaccination program. In the supplementary material, a detailed description of the time course on vaccination timelines is available (**Supplementary Material**). By the 25th of October 2021 126'586 individuals, equalling 63% of the canton's population (201'354 total inhabitants in October 2021³⁶), were fully vaccinated against SARS-COV-2 with either BNT162b2 (Pfizer/BioNTech), mRNA-1273 (Moderna), or Ad26.COV2.S (Janssen).

Study design and population. We conducted an exploratory retrospective case-control study from 28th of December 2020 to 25th of October 2021. Inclusion criteria for the *case cohort* were: (i) Individuals fully vaccinated in the Canton of Basel-City, including in retirement and nursing homes and hospitals, (ii) people living in the Canton of Basel-City: including Basel, Bettingen, and Riehen, and (iii) people with either SCoV2 specific NAT or antigen-test confirmed infection. Inclusion criteria for the *control cohort* were: (i) Individuals fully vaccinated at the cantonal vaccination center or at health care institutions, pharmacies, and hospitals; and (ii) people living in the Canton of Basel-City including Basel, Bettingen, and Riehen. The exclusion criterion for the case cohort was a positive NAT result considered as residual finding from a SARS-CoV-2 infection before the final vaccination. There were no exclusion criteria for the control group.

Data collection. Data on all vaccinated individuals were collected from the Vaccination Monitoring Data Lake (VMDL) of Switzerland and the Corona Vaccination Centre for the Canton of Basel-City. All vaccinating sites in Switzerland are obliged to report to the national register according to the Swiss Epidemic law, with a 100% coverage of the canton's total population. Data on positive tested individuals with a breakthrough infection were collected through the cantonal contact tracing database. All individuals with residence in the Canton of Basel-City tested positive for SCoV2 (RNA and antigen) are being reported to the Federal

Office of Public Health (FOPH) and through there to the cantonal Contact Tracing. Thereafter each positive tested individual is contacted and monitored throughout the isolation, whereby personal and clinical information is being collected for source identification. For hospitalized individuals the clinical information is being collected through the attending physician or nurse. We identified two sub-control groups: control group 1 comprises individuals fully vaccinated against COVID-19, who got vaccinated in all health care institutions, pharmacies and hospitals, including the vaccine center Basel city. Control group 2 is a subgroup of control group 1 and comprises individuals fully vaccinated against COVID-19 in the Corona Vaccination Centre for the Canton of Basel-City. Although meant as a control set, both control groups also comprise individuals who suffered from a breakthrough infection. Anonymization prevents tracking back individual information and thus prevents the exclusion of individuals with a breakthrough infection from the control sets.

Vaccine recipient characteristics have been collected as self-reported variables and were used to describe cases, to explain the probability of undergoing a breakthrough infection or to explain the probability of undergoing a breakthrough infection caused by either the Alpha or Delta SCoV2 variants. Supplementary table 1 shows an overview on control groups and patients with breakthrough infections (**Supplementary Table 1**).

The clinical course of infection was classified according to the National Institute of Health (NIH) COVID-19 treatment guidelines into “asymptomatic infection” (no symptoms), “mild illness” (various signs e.g., fever, cough; but no shortness of breath, dyspnea or abnormal chest imaging), “moderate illness” (evidence of lower respiratory disease and oxygen saturation (SpO₂) ≥94% on room air at sea level), “severe illness” (SpO₂ <94% on room air at sea level, PaO₂/FiO₂ <300 mm Hg, respiratory frequency <30 breaths/min, or lung infiltrates >50%), “critical illness” (respiratory failure, septic shock, and/or multiple organ dysfunction) and “death”³⁷.

SCoV2 lineage determination. At the University Hospital Basel, we used viral whole genome sequencing to determine the lineage in cases identified as breakthrough infection by Health Services of the Canton of Basel-City. Briefly, we used the Arctic protocol on a NextSeq 500 platform (Illumina), followed by the GOVGAP pipeline to determine the viral lineage as previously described^{38,39}. In a subset of samples the sequencing was done in another laboratory. These sequences could be accessed via the Swiss Pathogen Surveillance Platform (www.spsp.ch) and ENA and GISAID accessions. The accession numbers of the genomes used for this analysis are available in the supplementary table 7 (**Supplementary Table 2**).

Full vaccination. Full vaccination was defined as (a) seven days after the second BNT162b2 vaccine (Pfizer/BioNTech) or (b) seven days after the first BNT162b2 vaccine when the patient had a confirmed SCoV2 infection at least 30 days before the dose, (c) 14 days after the second mRNA-1273 (Moderna) vaccine or (d) 14 days after the first mRNA-1273 when the patient had a confirmed SARS-CoV-2 infection at least 30 days before the dose, (e) 14 days after a second ChAdOx1-S vaccine (AstraZeneca) and (f) 22 days after a single dose of Ad26.COVS.S (Janssen).

Breakthrough infection. A breakthrough infection was defined by a laboratory-confirmed SCoV2 infection through either SCoV2-specific nucleic acid testing (NAT) or antigen testing in fully vaccinated individuals. In Switzerland, positive antigen tests are recommended to be

confirmed by NAT to exclude the rare possibility of false-positive results whenever possible, thereby also providing access to samples for SCoV2 genome sequencing. The date of the breakthrough infection was set to the date of sample collection.

Statistical analysis. The analysis set is the full analysis set obtained by merging the case group with the control group 1 and 2 respectively. The data to be used in this study is information routinely collected at the time of vaccination or at the time of consultation in case of breakthrough infection. Missing values were not imputed. Hence statistical analyses were based on available case sets. All analyses were performed with R version 4.0.3 (2020-10-10). All variables were explored as a descriptive analysis including median and interquartile ranges of continuous variables unless otherwise indicated and as numbers and percentage for categorical variables.

Four models were used. The reported statistics for all models included: Odds-ratios, confidence intervals and associated p-values. Model 1: The analysis was conducted using control individuals from both group 1 and 2 respectively and case patients. The risk factors were included into a multivariate generalized linear model (GLM) with logit link-function and binomial distribution (logistic model) to investigate their potential association with the probability of suffering from a breakthrough infection or not. Model 2: In order to investigate whether the two control subgroups represented two different populations and whether the same or different risk factors are associated with the probability of a breakthrough infection when using control group 1 or 2, we ran two additional multivariate GLMs including the same risk factors but using either the dataset comprising control individuals from group 1 and case patients or the dataset comprising control individuals from group 2 and case patients. Model 3: In order to investigate whether severe immunosuppression further explains the probability of undergoing a breakthrough, we ran another multivariate GLM including all risk factors used in the previous models plus severe immunosuppression. This analysis was carried out on a dataset comprising control individuals from control group 2 and case patients. Model 4: To investigate which, if any, risk factors are associated with the probability of undergoing a breakthrough infection caused by the Alpha or Delta SCoV2 variants, we conducted a multivariate GLM with logit link-function and binomial distribution including the case group risk factors.

Although p-values were provided, readers should be aware that these cannot be used to accept or reject the null or the alternative hypothesis based on some predefined thresholds. P-values assess the compatibility of the data with the null hypothesis on a continuous scale. The data interpretation is not based on an arbitrary dichotomous threshold nor on p-values alone, but by combining p-values with a thorough examination of the effect size (odds-ratio) and considering the amount of uncertainty (error) around it (95% confidence interval).

Results

Occurrence of breakthrough infections. We identified a total of 492 patients (0.39%) with breakthrough infections in an overall population of 126'586 vaccine recipients. First, we analyzed the time distribution, in days, elapsed from full vaccination to the positive SCoV2 test result for all patients with breakthrough infections. The time to a positive SCoV2 test shows that most breakthrough infections occurred between a few days to about 170 days after full vaccination, with a median of 78 days (interquartile range, IQR 47-124 days). The

data suggests a weak bi-modal distribution, with a much weaker peak after 180 days. Accordingly, a steady increase of breakthrough infections starting after about 10-20 days post-vaccine and gradually levelling off after about 130 days in the frequency and cumulative frequency distributions (**Figure 1**). The burden of breakthrough infections correlated with the occurrence of overall SCoV2 cases in the observed community (**Supplementary Figure 1**).

Clinical case presentation. We further analyzed all available patient characteristics for vaccine recipients, who suffered from a breakthrough infection (**Supplementary Table 3**). Briefly, patients with a breakthrough infection had a median age of 45 years (IQR 32-64) and were slightly more often female (52.6%). The mRNA-1273 (Moderna) and BNT162b2 mRNA (Pfizer/BioNTech) were the two most commonly used COVID19 vaccines in our region, accounting for 99.2% of vaccine applications. Generally, people with breakthrough infections had an asymptomatic presentation or mild illness (26/492, 5.3% and 452/492, 91.9%). Only a minority of patients required hospitalization (14/492, 2.8%). Severe illness (5/492, 1.0%) and critical illness or death (2/492, 0.2%) were very rare. Patients requiring hospitalization were generally older compared to patients who did not require hospitalization (median age 82 years vs. 44 years). Hospitalized patients also showed more common predisposing risk-factors compared to non-hospitalized patients e.g., cardiac disease 64.3% vs 6.5% and arterial hypertension 50% vs. 14% (**Supplementary Table 4**). Similarly, patients who showed moderate, severe and critical illness also showed higher age (77, 81, and 87 years) and were having more predisposing risk factors compared to patients with asymptomatic or mild disease e.g., cardiac disease 71.4%, 80%, and 100% (**Supplementary Table 5**). In a subset of patients, we could also determine the Alpha and Delta SCoV2 variants. The Delta variant showed more breakthrough infections compared to the Alpha variant in absolute numbers. Of note, this reflected the epidemiological situation in the general population during the observational period, where the Delta variant was the dominant virus lineage in Fall 2021.

Next, we compared patients with breakthrough infections to all vaccine recipients using the two control groups: control group 1 (n=126'586) and 2 (n=109'382) (**Table 1**). The median age in patients with SCoV2 breakthrough infection was slightly lower compared to the control group 1 and 2 (median 45 years vs. 49 years vs. 52 years). The patients with SCoV2 breakthrough infections were more frequently vaccinated with the Pfizer/BioNTech vaccine compared to the control group 1 and 2 (47% vs. 33.5% vs. 33.1%). Also notable is that people at especially high risk according to the Federal Office of Public Health e.g., with a chronic disease (detailed list of conditions in **Supplementary Table 6**, which is a key indication for vaccination) suffered more frequently from breakthrough infection than the control group 1 and 2 (31.9% vs. 20.5% vs. 22.4%). Next, we compared characteristics, which were only available in patients with a breakthrough infection and people of control group 2 (which is a subset of control group 1). We observed slightly more breakthrough infections in patients with severe immunosuppression (5.3% vs. 3.0%) and less people who had serious side-effects after previous vaccines (0.2% vs. 1.0%) (**Table 1**).

	Level	Breakthrough	Control 1	Control 2	%Miss
n		492	126586	109382	
Gender (%)	Man	233 (47.4%)	60640 (47.9%)	52768 (48.2%)	0

	Woman	259 (52.6%)	65944 (52.1%)	56610 (51.8%)	
Age, median (IQR)		45 (32-64)	49 (34-65)	52 (36-68)	0
Type of vaccine, n (%)	Moderna Pfizer/BioNTech Janssen AstraZeneca	257 (52.2%) 231 (47%) 3 (0.6%) 1 (0.2%)	84200 (66.5%) 42386 (33.5%) 0 (0%) 0 (0%)	73125 (66.9%) 36257 (33.1%) 0 (0%) 0 (0%)	0
Indication for vaccination					
Chronic disease, n (%)	No Yes	335 (68.1%) 157 (31.9%)	100668 (79.5%) 25918 (20.5%)	84756 (77.6%) 24526 (22.4%)	0.1
Healthcare worker, n (%)	No Yes	432 (87.8%) 60 (12.2%)	114221 (90.2%) 12365 (9.8%)	101868 (93.2%) 7414 (6.8%)	0.1
Close contact to high-risk person, n (%)	No Yes	366 (74.4%) 126 (25.6%)	94629 (74.8%) 31957 (25.2%)	82007 (75.0%) 27275 (25.0%)	0.1
Serious side-effects previous vaccine*, n (%)	No Yes	491 (99.8%) 1 (0.2%)	N/A	108194 (99.0%) 1084 (1.0%)	0.1
Severe immunosuppression, n (%)	No Yes	466 (94.7%) 26 (5.3%)	N/A	105994 (97.0%) 3288 (3.0%)	0.1
Acute fever n, (%)	No Yes	492 (100%) 0 (0%)	N/A	106505 (100%) 46 (0%)	2.6
Contact community (%)	No Yes	470 (95.5%) 22 (4.5%)	126544 (100%) 42 (0)	N/A	0
Pregnant (%)	No Yes	491 (99.8%) 1 (0.2%)	124482 (99.7%) 339 (0.3%)	107790 (99.8%) 215 (0.2%)	1.3
Recovered from COVID (%)	No Yes	486 (98.8%) 6 (1.2%)	121730 (96.2%) 4856 (3.8%)	106178 (97.1%) 3204 (2.9%)	0

Table 1. Comparison of patients with breakthrough infections compared to all control vaccine recipients using the control sets. Categorical variables are presented with numbers and percentages. *Serious side-effects in previous vaccines focuses on any vaccine and is a self-reported variable. Since age shows some departure from normality in the case group, it is presented with median and [Interquartile range].

Identification of potential risk factors. Next, we identified potential risk factors related to the probability of suffering from a breakthrough infection using generalized linear models. We compared patients with a breakthrough infection towards control group 1 (**Table 2**) and control group 2 (**Supplementary Table 7**). Overall, both multivariate regression models including control group 1 and 2 showed comparable results.

A higher age was associated with a lower odds for breakthrough infections (OR 0.987, 95% CI 0.983-0.992). Therefore, we further explored, if breakthrough infections were differently distributed between the age quartiles. Whereas 16 to 64 years old patients showed breakthrough infections mainly from July to October 2021, corresponding to infections caused by the Delta SCoV2 variant, patients above 64 years old showed a first bulk of breakthrough infections from January to May 2021, corresponding to infections caused by the alpha variant, and a second, more important bulk from July to October corresponding to infections caused by the Delta variant (**Figure 2**), suggesting a different epidemiology as

younger age groups could not get the vaccine as early, hence no breakthrough infection was possible.

Breakthrough infections were more common in people vaccinated with the Pfizer/BioNTech vaccine (OR 1.459), with chronic disease (OR 2.109) and in healthcare workers (OR 1.404). Patients who recovered from COVID-19 prior to vaccination were less likely to suffer from a breakthrough infection (OR 0.296). We did not observe a significantly increased risk for immunosuppressed patients (OR 1.248, 95% CI 0.806-1.849). Patients with (self-declared) serious side-effects from previous vaccines show a slightly lower risk for breakthrough infection (OR 0.289, 95% CI 0.033-1.035) (**Supplementary Table 8**). We also performed a subgroup analysis focusing on breakthrough infection with the Delta variant (**Supplementary Table 9 and 10**).

	n	Odds ratio	CI	p
Intercept	125308	0.006	(0.005-0.008)	<0.001
Age		0.987	(0.983-0.992)	<0.001
Gender (woman vs. man)		1.037	(0.867-1.242)	0.692
Vaccine (Pfizer/BioNTech, ref =Moderna)		1.459	(1.238-1.612)	<0.001
Chronic disease (=Yes)		2.109	(1.692-2.620)	<0.001
Healthcare worker (=Yes)		1.404	(1.042-1.860)	0.022
Close contact with high-risk person (=Yes)		0.902	(0.724-1.116)	0.349
Pregnant (=Yes)		0.671	(0.038-2.995)	0.691
Recovered from COVID-19 (=Yes)		0.296	(0.117-0.606)	0.003

Table 2. Multivariable logistic regression exploring the relationships between potential risk factors and the probability to suffer from a SCoV2 breakthrough infection using the 'control' set 1. Only Moderna and Pfizer/BioNTech vaccines are compared, because no other vaccine was used in the control population. A generalized linear mixed model was used.

Difference between breakthrough infections with Alpha or Delta SCoV2 variants. Next, we explored potential differences between breakthrough infections caused by the Alpha or Delta SCoV2 variants (**Table 3**). Supplementary Figure 2 and 3 show detailed time distributions for breakthrough infection caused by these variants (**Supplementary Figure 2 and 3**). Based on the Swiss national surveillance program for SCoV2 and shared data efforts of the Swiss Pathogen Surveillance Platform (www.spsp.ch), we know that during Fall 2021 about 97% of the circulating viruses in Switzerland were Delta variants and subtypes thereof (<https://www.covid19.admin.ch/en/>). The sequences of the viral isolates identified are part of normal phylogenetic distribution and do not show specific unusual mutations e.g., in the viral Spike protein (data not shown). Of note, during the observational period we have not observed the newly discovered Omicron variant (B.1.529). Currently this variant rapidly increases and accounts for approximately 7% of cases in Switzerland (as of 10th December 2021, <https://www.covid19.admin.ch/en/>).

The Alpha variant was dominating from February to June 2021 and then replaced by the Delta variant in May 2021. During this time also the vaccination concept and availability

changed by providing access to individuals without high-risk disease and younger people. No difference regarding the time to positive test could be observed between the two variants. However, the two variants showed very different baseline characteristics. The median age for patients with breakthrough infection caused by the Alpha variant was 82 years and for the Delta variant only 41.5 years. This shows that breakthrough infections over time occurred in very different populations. The age difference is also reflected in the distribution of reasons for vaccination e.g., the proportion of chronic diseases (91.7% in Alpha vs. 26.2% in Delta) or living in a high-risk community facility (41.7% vs. 0.8%). Although the median time, in days, from vaccination to a confirmed SCoV2 breakthrough infection was different with 42 days in the Alpha variant compared to 69 days in the Delta variant, this difference was not significant. It also seems that case severity in Alpha variants was higher compared to Delta variants, e.g., severe and critical illnesses accounted for 25% (Alpha) and 1.6% (Delta), which could also reflect the same issue of a more vulnerable population. For the Alpha variant, breakthrough infection was also more often linked to retirement and nursing homes (41%), whereas for the Delta variant mainly linked to holidays and work (23.1% and 6.9%).

Variable	Level	SCoV2-Alpha	SCoV2-Delta	% missing
n		12	258	
Age, med (IQR)	Years	82.0 (70.5-87.0)	44.0 (32.0-61.8)	45.1
Sex, n (%)	Man Woman	5 (41.7%) 7 (58.3%)	124 (48.1%) 134 (51.9%)	45.1
Type of vaccine, n (%)	Moderna Pfizer/BioNTech Janssen AstraZeneca	1 (8.3%) 11 (91.7%) 0 (0%) 0 (0%)	136 (52.7%) 120 (46.5%) 1 (0.4%) 1 (0.4%)	45.1
Indication for vaccination				
Chronic diseases, n (%)	No Yes	1 (8.3%) 11 (91.7%)	183 (70.9%) 75 (29.1%)	45.1
Healthcare worker, n (%)	No Yes	12 (100%) 0 (0%)	222 (86.0%) 36 (14.0%)	45.1
Close contact to high-risk person, n (%)	No Yes	6 (50%) 6 (50%)	191 (74.0%) 67 (26.0%)	45.1
Serious side effects to other vaccines*, n (%)	No Yes	12 (100%) 0 (0%)	257 (99.6%) 1 (0.4%)	45.1
Severe immunosuppression, n (%)	No Yes	9 (75%) 3 (25%)	247 (95.7%) 11 (4.3%)	45.1
Acute fever, n (%)	No Yes	12 (100%) 0 (0%)	258 (100%) 0 (0%)	45.1
Pregnant, n (%)	No Yes	12 (100%) 0 (0%)	257 (99.6%) 1 (0.4%)	45.1
Recovered from COVID19, n (%)	No Yes	12 (100%) 0 (0%)	256 (99.2%) 2 (0.8%)	45.1
Time vacc to 1st symptoms, median (IQR)	days	59 (57-61)	75 (44-118)	45.1

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Time vacc/Delta outbreak to 1st symptoms, median (IQR)	days	59 (57-61)	49.5 (28.3-72.0)	45.1
Time vacc to 1st symptoms for Alpha & Delta patients vaccinated after Delta outbreak, median (IQR)	days	59 (57-61)	40 (23-57)	45.1
Time vacc to positive test, median (IQR)	days	42 (17-63)	77 (46-120)	45.1
Time vacc/Delta outbreak to positive test, median (IQR)	days	42 (17-63)	49 (31-72)	45.1
Time vacc to positive test for Alpha & Delta patients vaccinated after Delta outbreak, median (IQR)	days	42 (17-63)	45 (26-59)	45.1
PCR ct value, median (IQR)		20 (20-20)	20.02 (17.22-23.18)	45.1
Severity of disease, n (%)	Asymptomatic Mild illness Moderate illness Severe illness Critical illness and death	2 (16.7%) 7 (58.3%) 0 (0%) 2 (16.7%) 1 (8.3%)	6 (2.3%) 244 (94.6%) 5 (1.9%) 2 (0.8%) 1 (0.4%)	45.1
Hospitalisation	No Yes	11 (91.7%) 1 (8.3%)	127 (96.9%) 8 (3.1%)	45.1
Source of infection	Club, party, bar Cultural event Family Friends Holidays Hospital Religion Retirement and nursing home School Sports Unknown Work	0 (0%) 0 (0%) 3 (25%) 0 (0%) 1 (8.3%) 1 (8.3%) 0 (0%) 5 (41%) 0 (0%) 0 (0%) 2 (16.7%) 0 (0%)	12 (4.7%) 4 (1.6%) 72 (27.9%) 14 (5.4%) 63 (24.4%) 3 (1.2%) 1 (0.4) 10 (3.9%) 1 (0.4%) 3 (1.2%) 58 (22.5%) 17 (6.6%)	45.1
Baseline risk factor				
Chronic lung disease	No Yes	11 (91.7%) 1 (8.3%)	243 (94.2%) 15 (5.8%)	45.1
Chronic renal disease	No Yes	11 (91.7%) 1 (8.3%)	254 (98.4%) 4 (1.6%)	45.1
Cancer	No Yes	10 (83.3%) 2 (16.7%)	253 (98.1%) 5 (1.9%)	45.1
Cardiac disease	No Yes	7 (58.3%) 5 (41.7%)	240 (93.0%) 18 (7.0%)	45.1
Arterial hypertension	No Yes	9 (75%) 3(25%)	215 (83.3%) 43 (16.7%)	45.1

Diabetes	No	10 (83.3%)	234 (90.7%)	45.1
	Yes	2 (16.7%)	24 (9.3%)	
Obesity	No	11 (91.7%)	257 (99.6%)	45.1
	Yes	1 (8.3%)	1 (0.4%)	

Table 3. Comparisons of patient characteristics between individuals who suffered from a breakthrough infection caused by the Alpha or the Delta variant. Categorical variables are presented with numbers and percentages. *Serious side-effects in previous vaccines focuses on any vaccine and is a self-reported variable. Variables showing departure from normality are presented with median and [Interquartile Range].

Supplementary Table 8 summarizes the results of a generalized linear model with binomial distribution investigating potential risk factors associated with the relative probability of being infected by the Delta variant (vs. Alpha variant taken as a reference) in case of breakthrough infection (**Supplementary Table 8**).

Discussion

Our study explores the key factors associated with COVID19 vaccine breakthrough infection and compares the patient characteristics between people with a breakthrough infection caused by either the Alpha or Delta SCoV2 variant. The key findings of our study are: (i) breakthrough infections are very rare with only 0.39% (492/126586) of the vaccinated population being affected during a 10 months observation period; (ii) breakthrough infections were either asymptomatic or mild (97.2%) with only 2.8% of patients (14/492) requiring hospitalization (14/126586; 0.01%); (iii) most of the breakthrough infection in our population occurred between a few days to about 170 days after full vaccination, with a median of only 78 days for the time to a positive SCoV2 test.

In our cohort, older individuals are less likely to suffer from a breakthrough infection. This may be due to younger individuals being more likely to travel, enjoy social events outside their home and thus be more exposed to the Delta variant, which caused most of the breakthrough infections in our study^{40,41}. Especially after vaccination, young and healthy individuals might feel secure, leading to a higher risk behavior. Similarly, individuals with close contact to a high-risk person were less likely to suffer from a breakthrough infection. This finding is most probably explained due to the more vigilant behavior as well and underlines the fact that incautious behavior might be a greater risk factor for breakthrough infection than intrinsic risk factors such as age or chronic disease.

We also observed that individuals who recovered from a previous COVID-19 infection are less likely to suffer from a breakthrough infection. This is of interest particularly because the previous infection was caused by the Alpha variant whereas the breakthrough infection was caused by the Delta SCoV2 variant in this patient subgroup. The natural infection may build different types of immune response and additional immunological memory against other viral proteins^{42,43}, recently termed hybrid immunity⁴⁴. Further studies regarding breakthrough infections in COVID-19 recovered patients will show whether a previous infection with the Alpha or Delta SARS-CoV-2 variant leads to sufficient protection against the emerging Omicron virus variant.

Our study indicates that individuals with a chronic disease are more likely to suffer from a breakthrough infection. Similar findings have been made mainly for the elderly with overall more chronic diseases ^{14,45,46}.

Individuals vaccinated with the Pfizer/BioNTech vaccine (BNT162b2) are more likely to suffer from a breakthrough infection than individuals vaccinated with the Moderna vaccine (mRNA-1273). Tenforde and colleagues also showed that the mRNA-1273 vaccine was significantly more protective (OR, 0.11) compared with the BNT162b2 vaccine (OR, 0.19). The protective association against hospitalization for the BNT162b2 vaccine more than 120 days following vaccination declined notably (OR, 0.36; median, 143 days from vaccine dose 2 to illness onset), whereas the effectiveness of the mRNA-1273 vaccine more than 120 days post-vaccination was largely preserved (OR, 0.15; median, 141 days from vaccine dose 2 to illness onset) ⁶. Our study provides important confirmation and points out that risk groups for more severe clinical outcomes may benefit from the Moderna vaccine, due to the reduction in breakthrough infections.

Of particular relevance for the emerging new wave of Omicron is our observation that healthcare workers are more likely to suffer from a breakthrough infection. This is an important finding and highlights the importance for booster vaccines in this cohort. A recent publication showed 39 cases of breakthrough infection in a total 1497 healthcare workers, which was particularly linked to titers of SARS-CoV-2 neutralizing antibodies ⁵ and another study identified 4 of 1388 (0.3%) breakthrough infections in fully vaccinated compared to 21 of 585 (3.6%) in non-vaccinated staff of a long-term care facility. Most likely the increased risk of breakthrough infection in healthcare workers is explained through a higher exposure to infected people.

Further, in our cohort, most breakthrough infections were caused by the Delta variant. However, interpreting the temporal dynamics of infection relative to vaccination for the Alpha and Delta variant is difficult since these variants emerged at different time points relative to the availability of vaccination in Switzerland. Consequently, the median time to positive test does not necessarily demonstrate the ability of the vaccine to protect individuals from a SCoV2 infection, but is probably biased by the variant itself and the non-pharmaceutical public health measures during the course of the study. Our additional models focussing only on individuals vaccinated after the emergence of the Delta variant, show a median time of 38 days (IQR 17-54) to SCoV2-positive testing. As the subgroup analysis resulted in a loss of statistical power, the cumulative distributions no longer can resolve whether or not a breakthrough infection is more likely to occur as more time elapsed since full vaccination. Other studies have reported an increasing risk with a longer time since vaccination ²⁰. In our vaccine control cohort, the median time since vaccination was 115 days (IQR 84-145, min=0, max=273) and 82 days (IQR 51-100, min=0, max=111) for individuals vaccinated after the Delta outbreak. The hypothesis of breakthrough infections increasing with elapsed time since full vaccination must consider new circulating SCoV2 variants and the overall increase in case numbers during this period. Indeed, our results are consistent with the notion that individuals infected with the Delta variant were at higher risk for breakthrough infection compared to individuals infected with the Alpha variant. Although, we have not determined prospectively neutralization antibody titers, this phenomenon is most likely explained by the amino acid changes on the virus spike protein and subsequently the resulting lower neutralization efficiency ^{24,28} and the general higher number of infected individuals with the Delta variant.

Surveillance of viral evolution using whole genome sequencing on a national scale remains critical for the months to come. As shown in our data as well, the clinical course of vaccine breakthrough infection has been described as generally mild (<https://www.cdc.gov/coronavirus/2019-ncov/vaccines/effectiveness/why-measure-effectiveness/breakthrough-cases.html>), with a few exceptions ⁴⁷. It is therefore crucial to also closely monitor the frequency and severity of SARS-CoV-2 breakthrough infections, including the clinical course, and combine this information with surveillance of viral evolution associated with reducing vaccine effectiveness, and their clinical course in fully vaccinated individuals with breakthrough infection. This has been done in retrospect but based on reported databases real-time monitoring of breakthrough infection should be initiated.

Limitations. Our study has several important limitations. During the study timeframe, diagnostic and screening tests on SARS-CoV-2 for vaccinated individuals were only recommended by the Federal Office of Public Health (FOPH) when symptoms occurred or when the vaccinated individual lived in the same household as an individual tested positive for SARS-CoV-2. Therefore, although all positive test results are being reported to the FOPH, missing data on breakthrough infections in e.g., asymptomatic patients is possible. Due to different reporting systems, information regarding immunosuppression in the control population is only available for individuals vaccinated in the Corona Vaccination Centre for the Canton of Basel-City and not for individuals vaccinated in other sites such as pharmacies or hospitals. Because only vaccinating institutions in Switzerland are obligated to report to the Swiss COVID-19 vaccination register, individuals with residence in the Canton of Basel-City vaccinated outside of Switzerland are not recorded in the database. Accordingly, individuals vaccinated with ChAdOx1-S only appear in the case group. We included a relatively small number of sequenced cases with breakthrough infection - sequencing was available only for a subset of PCR confirmed cases (approximately 5-10%) of all cases are part of a nation wide surveillance program. Although we have not sequenced all strains, it is unlikely that we have missed a substantial dominant new lineage causing breakthrough infection, as the lineages dominating during the observational period were also found in other parts of the country as dominant lineages and also in the surrounding neighboring countries. Also, we do not have neutralizing antibody titers available for the whole cohort, however, this is also not a suitable assay for a general and large population.

Conclusion. Overall our study shows that breakthrough infections are rare and mild, and that the highest risk is early after vaccination - more than 50% of breakthrough infections occur 70 to 80 days post-vaccine. This clearly implies that boost vaccination should be much earlier initiated compared to the currently communicated 180 day threshold. This has important implications especially for risk groups associated with more frequent breakthrough infections such as healthcare workers, and people in high risk care facilities. Due to changes in the epidemiological dynamic with new variants emerging, continuous monitoring of breakthrough infection may be very helpful to provide evidence on booster vaccines and patient groups at risk for potential complications.

Funding

No specific funding was received for this study. The authors declare no conflict of interest.

Acknowledgment

We thank the members of the different SARS-CoV-2 vaccination teams in Basel. We also want to thank the Swiss Pathogen Surveillance Platform (www.spsp.ch) for providing access to genomes and lineage related information of cases with breakthrough infection.

Figure legends

Figure 1. Distribution time in days from full vaccination (as defined above) to the positive SCoV2 test result confirming all cases of breakthrough infection. Upper panel, absolute frequency; lower panel, cumulative frequency.

Figure 2. Age quartiles and distribution of breakthrough infections.

Supplementary Figure 1. SARS-CoV-2 PCR confirmed cases after introduction of the vaccine. The red line shows all breakthrough infections and the black line shows all PCR confirmed cases (secondary axis) in Basel-City.

Supplementary Figure 2. Distribution time in days from full vaccination (as defined) to the breakthrough infections with the Alpha variant. Upper panel, absolute frequency; lower panel cumulative frequency.

Supplementary Figure 3. Distribution time in days from full vaccination (as defined) to the breakthrough infections with the Delta variant. Upper panel, absolute frequency; lower panel cumulative frequency.

Supplementary Figure 3.

Tables

Table 1. Comparison of patients with breakthrough infections compared to all control vaccine recipients using the control sets. Categorical variables are presented with numbers and percentages. Since age shows some departure from normality in the case group, it is presented with median and [Interquartile range].

Table 2. Multivariable logistic regression exploring the relationships between potential risk factors and the probability to suffer from a SARS-CoV-2 breakthrough infection using the 'control' set 1. Only Moderna and Pfizer/BioNTech vaccines are compared, because no other vaccine was used in the control population. A generalized linear mixed model was used.

Table 3. Comparisons of patient characteristics between individuals who suffered from a breakthrough infection caused by the Alpha or the Delta variant. Categorical variables are presented with numbers and percentages. Variables showing departure from normality are presented with median and [Interquartile Range].

Supplementary Table 1. Collected vaccine recipient and patient characteristics. * other reasons than age, healthcare worker, chronic disease, contact with vulnerable person, living in a community with increased risks. * general previous side effects.

Control group 1	Control group 2	Breakthrough infections
Age		Age
Gender, (male/female), count & percentage	Gender, (male/female), count & percentage	Gender, (male/female), count & percentage
Type of vaccine; categorical, Pfizer/BioNTech, Moderna, Janssen, AstraZeneca; count & percentage	Type of vaccine; categorical, Pfizer/BioNTech, Moderna, Janssen, AstraZeneca; count & percentage	Type of vaccine; categorical, Pfizer/BioNTech, Moderna, Janssen, AstraZeneca; count & percentage
Chronic disease, (Yes/No)	Chronic disease, (Yes/No)	Chronic disease, (Yes/No)
Healthcare worker, (Yes/No)	Healthcare worker, (Yes/No)	Healthcare worker, (Yes/No)
Close contact to high-risk person, (Yes/No)	Close contact to high-risk person, (Yes/No)	Close contact to high-risk person, (Yes/No)
Vaccination for other reasons*, (Yes/No)	N/A	
Pregnancy, (Yes/No)	Pregnancy, (Yes/No)	Pregnancy, (Yes/No)
Person recovered from COVID-19, (Yes/No)	Person recovered from COVID-19, (Yes/No)	Person recovered from COVID-19, (Yes/No)
Date of full vaccination	Date of full vaccination	Date of full vaccination
N/A	Severe immunosuppression, (Yes/No)	Severe immunosuppression, (Yes/No)
N/A	Serious previous side effects*, (Yes/No)	Serious side effects, (Yes/No)
N/A	Acute fever before / during COVID-19 vaccination, (Yes/No)	Acute fever before / during COVID-19 vaccination, (Yes/No)
N/A	N/A	Time between full vaccination and positive test
N/A	N/A	Time between full vaccination and first symptoms
N/A	N/A	SARS-CoV-2 variant, (Alpha or Delta), count & percent
N/A	N/A	Hospitalisation, (Yes/No)
N/A	N/A	Suspected source of infection: club, party, bar; cultural event; family; friends; holidays; hospital; religion; retirement and nursing home; school; sports; work; unknown;
N/A	N/A	Chronic lung disease, (Yes/No)
N/A	N/A	Chronic renal disease, (Yes/No)

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

N/A	N/A	Cancer, (Yes/No)
N/A	N/A	Cardiovascular disease, (Yes/No)
N/A	N/A	Arterial hypertension, (Yes/No)
N/A	N/A	Diabetes, (Yes/No)
N/A	N/A	Obesity, (Yes/No)

Supplementary Table 2. Accession numbers of used genomes in this analysis.

GISAID Identifier	Pangolin Lineage
EPI_ISL_3086290	AY.4
EPI_ISL_4903597	AY.4
EPI_ISL_4903635	AY.102
EPI_ISL_5049804	AY.102
EPI_ISL_5307606	AY.46
EPI_ISL_5307608	AY.43
EPI_ISL_5307610	AY.54
EPI_ISL_5307620	AY.43
EPI_ISL_5307622	AY.14
EPI_ISL_5307667	AY.46
EPI_ISL_5307709	AY.102
EPI_ISL_5428846	AY.4
EPI_ISL_5428847	AY.41
EPI_ISL_5428848	AY.4
EPI_ISL_5428849	AY.46.6
EPI_ISL_5428850	AY.111
EPI_ISL_5508919	AY.43
EPI_ISL_5508977	AY.98.1
EPI_ISL_5508986	AY.98.1
EPI_ISL_5508994	AY.43
EPI_ISL_5509063	AY.80
EPI_ISL_5509099	AY.47
EPI_ISL_5509125	AY.33
EPI_ISL_5509131	AY.33
EPI_ISL_5509160	AY.43

EPI_ISL_5509166	AY.4
EPI_ISL_5765992	AY.43
EPI_ISL_5766012	AY.95
EPI_ISL_5766062	AY.43
EPI_ISL_5766070	AY.43
EPI_ISL_5766077	AY.43
EPI_ISL_5766144	AY.43
EPI_ISL_5766182	B.1.617.2
EPI_ISL_5766183	AY.20
EPI_ISL_5766195	B.1.617.2
EPI_ISL_5766203	AY.43
EPI_ISL_5766208	AY.43
EPI_ISL_5766269	AY.46.6
EPI_ISL_5841634	AY.44
EPI_ISL_5841635	AY.54
EPI_ISL_5841657	AY.4
EPI_ISL_5841661	AY.102
EPI_ISL_5841666	AY.43
EPI_ISL_5841685	AY.4
EPI_ISL_5841691	AY.102
EPI_ISL_5841709	AY.9.2
EPI_ISL_5933964	AY.102
EPI_ISL_5933970	AY.102
EPI_ISL_5934004	AY.4
EPI_ISL_5934005	AY.102
EPI_ISL_5934006	AY.43

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

EPI_ISL_5934007	AY.43
EPI_ISL_5934008	AY.4
EPI_ISL_5934009	AY.102
EPI_ISL_5934010	AY.46.6
EPI_ISL_6015872	AY.44
EPI_ISL_6015873	AY.43
EPI_ISL_6015874	AY.43
EPI_ISL_6015875	AY.43
EPI_ISL_6157569	AY.54
EPI_ISL_6157570	AY.102
EPI_ISL_3086299	AY.70
EPI_ISL_5841659	AY.43
EPI_ISL_1747622	B.1.1.7
EPI_ISL_1747636	B.1.1.7
EPI_ISL_1747641	B.1.1.7
EPI_ISL_1748263	B.1.1.7
EPI_ISL_1748463	B.1.1.7
EPI_ISL_1914607	B.1.1.7
EPI_ISL_2270095	B.1.1.7
EPI_ISL_2466583	B.1.1.7
EPI_ISL_3030104	AY.98.1
EPI_ISL_3030113	AY.43
EPI_ISL_3086318	AY.42
EPI_ISL_3086319	B.1.617.2
EPI_ISL_3184351	AY.43
EPI_ISL_3184366	AY.9.2
EPI_ISL_3229188	B.1.1.7

EPI_ISL_3229190	AY.43
EPI_ISL_3229201	AY.43
EPI_ISL_3229213	B.1.617.2
EPI_ISL_3229214	B.1.617.2
EPI_ISL_3229224	AY.5
EPI_ISL_3229225	AY.43
EPI_ISL_3229227	AY.43
EPI_ISL_3229248	AY.4
EPI_ISL_3247301	AY.43
EPI_ISL_3247308	AY.42
EPI_ISL_3247349	AY.98.1
EPI_ISL_3303743	AY.43
EPI_ISL_3303758	AY.42
EPI_ISL_3344075	AY.42
EPI_ISL_3344101	AY.4
EPI_ISL_3344102	AY.43
EPI_ISL_3344111	B.1.617.2
EPI_ISL_3425805	AY.98.1
EPI_ISL_3425806	AY.34
EPI_ISL_3451674	AY.43
EPI_ISL_3451732	AY.43
EPI_ISL_3451733	AY.43
EPI_ISL_3530135	AY.42
EPI_ISL_3530171	AY.94
EPI_ISL_3530179	AY.23
EPI_ISL_3530776	AY.43
EPI_ISL_3530792	AY.98.1

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

EPI_ISL_3530842	AY.34
EPI_ISL_3570114	AY.16
EPI_ISL_3570115	B.1.617.2
EPI_ISL_3570127	AY.43
EPI_ISL_3570128	B.1.617.2
EPI_ISL_3570130	AY.43
EPI_ISL_3710254	AY.4
EPI_ISL_3710255	AY.98.1
EPI_ISL_3730669	AZ.2
EPI_ISL_3730670	AY.36
EPI_ISL_3824224	AY.42
EPI_ISL_3824225	AY.4
EPI_ISL_3824226	AY.98.1
EPI_ISL_3824227	AZ.2
EPI_ISL_3824228	AY.43
EPI_ISL_3824229	AY.43
EPI_ISL_3824230	AY.102
EPI_ISL_3824270	AY.12
EPI_ISL_4251188	AY.43
EPI_ISL_4251192	AY.43
EPI_ISL_4251219	AY.43
EPI_ISL_4392868	AY.43
EPI_ISL_4395046	AY.9.1
EPI_ISL_4395061	AY.43
EPI_ISL_4395072	AY.4
EPI_ISL_4395085	AY.104
EPI_ISL_4395102	AY.86

EPI_ISL_4395109	AY.43
EPI_ISL_4395150	AY.33
EPI_ISL_4395151	AY.9.2
EPI_ISL_4395152	AY.102
EPI_ISL_4395153	AY.9.2
EPI_ISL_4395154	AY.43
EPI_ISL_4395155	AY.42
EPI_ISL_4395156	AY.98.1
EPI_ISL_4395157	AY.4
EPI_ISL_4395158	AY.43
EPI_ISL_4395159	AY.4
EPI_ISL_4395160	B.1.617.2
EPI_ISL_4395161	B.1.617.2
EPI_ISL_4395162	B.1.617.2
EPI_ISL_4395163	AY.9.2
EPI_ISL_4395165	AY.9.2
EPI_ISL_4395166	AY.43
EPI_ISL_4395167	AY.9.2
EPI_ISL_4395168	AY.43
EPI_ISL_4395169	AY.46
EPI_ISL_4395170	AY.9.2
EPI_ISL_4395173	AY.9.2
EPI_ISL_4395288	AY.5
EPI_ISL_4395290	AY.5.4
EPI_ISL_4395301	AY.73
EPI_ISL_4395303	AY.43
EPI_ISL_4395308	AY.25

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

EPI_ISL_4410796	AY.43
EPI_ISL_4410804	AY.9.2
EPI_ISL_4410806	AY.4
EPI_ISL_4410862	AY.42
EPI_ISL_4410869	AY.46.6
EPI_ISL_4410890	AY.4
EPI_ISL_4450796	AY.102
EPI_ISL_4450798	B.1.617.2
EPI_ISL_4450800	AY.43
EPI_ISL_4450829	AY.42
EPI_ISL_4450830	AY.9.2
EPI_ISL_4450831	AY.9.2
EPI_ISL_4450832	B.1.617.2
EPI_ISL_4450833	AY.4
EPI_ISL_4450834	AY.4
EPI_ISL_4450835	AY.43
EPI_ISL_4450836	AY.98.1
EPI_ISL_4450837	AY.46.6
EPI_ISL_4450838	AY.46.6
EPI_ISL_4450839	AY.43
EPI_ISL_4450840	AY.9.2
EPI_ISL_4450841	AY.98.1
EPI_ISL_4450888	AY.42
EPI_ISL_4450889	AY.43
EPI_ISL_4450892	AY.33
EPI_ISL_4450897	AY.43
EPI_ISL_4450901	AY.43

EPI_ISL_4450904	AY.43
EPI_ISL_4542104	AY.25
EPI_ISL_4542107	AY.39
EPI_ISL_4542117	AY.23
EPI_ISL_4542185	AY.43
EPI_ISL_4571409	B.1.617.2
EPI_ISL_4571425	AY.43
EPI_ISL_4814044	B.1.617.2
EPI_ISL_4814050	AY.102
EPI_ISL_4814097	AY.43
EPI_ISL_4814115	AY.43
EPI_ISL_4903661	AY.102
EPI_ISL_4903668	AY.43
EPI_ISL_5307621	B.1.617.2
EPI_ISL_5307655	AY.43
EPI_ISL_5307682	B.1.617.2
EPI_ISL_5307686	AY.4.3
EPI_ISL_5307719	AY.43
EPI_ISL_5307727	AY.111
EPI_ISL_5307728	AY.46
EPI_ISL_5307730	AY.43
EPI_ISL_5509155	AY.43
EPI_ISL_5766178	AY.44
EPI_ISL_6307802	AY.4
EPI_ISL_6307803	B.1.617.2
EPI_ISL_6307804	AY.25
EPI_ISL_6307805	AY.102

It is made available under a [CC-BY 4.0 International license](#) .

EPI_ISL_6307806	AY.102
EPI_ISL_6307807	AY.43
EPI_ISL_6307808	AY.4
EPI_ISL_6307809	AY.42
EPI_ISL_6307810	AY.43

EPI_ISL_6307811	AY.25
EPI_ISL_6307812	AY.102
EPI_ISL_6307813	AY.102

Supplementary Table 3. Baseline characteristics for all individuals in the database with a confirmed breakthrough infection.

Variable	Level	Overall	% missing
n		492	
Gender (%)	Male Female	233 (47.4%) 259 (52.6%)	0
Age, median (IQR) in years		45.0 (32.00-64.00)	0
Vaccine type, n (%)	Moderna Pfizer/BioNTech Janssen AstraZeneca	257 (52.2%) 231 (47.0%) 3 (0.6%) 1 (0.2%)	0
Time full vaccine to 1st symptom, median (IQR)		78 (47-122)	7.5
Time full vaccine/Delta outbreak to 1st symptoms, median (IQR)		50 (29-72)	
Time full vaccine to 1st symptoms for Alpha & Delta patients vaccinated after Delta outbreak, median (IQR)		42 (25-59)	
Time full vaccine to positive test, median (IQR)		78 (47-124)	0.8
Time full vaccine/Delta outbreak to positive test, median (IQR)		49 (29-72)	
Time full vaccine to positive test for Alpha & Delta patients vaccinated after Delta outbreak, median (IQR)		45 (25-60)	
Indication for vaccine			
Chronic diseases, n (%)	No Yes	335 (68.1%) 157 (31.9%)	0
Healthcare worker, n (%)	No Yes	432 (87.8%) 60 (12.2%)	0
Close contact to high-risk person, n (%)	No Yes	336 (74.4%) 126 (25.6%)	0
Serious side effects to other vaccines, n (%)	No Yes	491 (99.8%) 1 (0.2%)	0
Severe immunosuppression, n (%)	No Yes	466 (94.7%) 26 (5.3%)	0
Acute fever, n (%)	No Yes	492 (100%) 0 (0%)	0
Recovered from COVID-19 (%)	No Yes	486 (98.8%) 6 (1.2%)	0
Pregnant (%)	No Yes	491 (99.8%) 1 (0.2%)	0

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Virus variant (%)	Alpha Delta Different or not classified	12 (2.4%) 258 (53.4%) 222 (45.1%)	45.1
PCR based Ct value, median (IQR)		20.45 (17.82 - 26.20)	60.2
Clinical severity (%)	Asymptomatic Mild illness Moderate illness Severe illness Critical illness and death	26 (5.3%) 452 (91.9%) 7 (1.4%) 5 (1.0%) 2 (0.4%)	0
Hospitalisation (%)	No Yes	478 (97.2%) 14 (2.8%)	0
Suspected source of infection (%)	Club, party, bar Cultural event Family Friends Holidays Hospital Religion Retirement and nursing home School Sports Unknown Work	17 (3.5%) 7 (1.4%) 135 (27.4%) 26 (5.3%) 106 (21.5%) 7 (1.4%) 3 (0.6%) 23 (4.7%) 9 (1.8%) 4 (0.8%) 119 (24.2%) 36 (7.3%)	0
Baseline risk factor			
Chronic lung disease (%)	No Yes	458 (93.1%) 34 (6.9%)	0
Chronic renal disease (%)	No Yes	484 (98.4%) 8 (1.6%)	0
Cancer (%)	No Yes	477 (97.0%) 15 (3.0%)	0
Cardiovascular disease (%)	No Yes	452 (91.9%) 40 (8.1%)	0
Arterial disease (%)	No Yes	417 (84.9%) 74 (15.1%)	0.2
Diabetes (%)	No Yes	451 (91.7%) 41 (8.3%)	0
Obesity (%)	No Yes	489 (99.4%) 3 (0.6%)	0

Supplementary Table 4. Baseline characteristics of patients with breakthrough infection who required hospitalization (n=14) compared to patients without hospitalization (n=478).

Variable	Level	Not hospitalized	Hospitalized	% missing
n		478	14	0
Age, med (IQR)	Years	44 (32.0-62.8)	82 (78.3-90.0)	0
Sex, n (%)	Man Woman	225 (47.1%) 253 (52.9%)	8 (57.1%) 6 (42.9%)	0
Type of vaccine, n (%)	Moderna Pfizer/BioNTech Janssen AstraZeneca	252 (52.7%) 222 (46.4%) 3 (0.6%) 1 (0.2%)	5 (35.7%) 9 (64.3%) 0 (0%) 0 (0%)	0
Variant	Alpha Delta	11 (4.2%) 250 (95.8%)	1 (11.1%) 8 (88.9%)	0
Indication for vaccination				
Chronic diseases, n (%)	No Yes	333 (69.7%) 145 (30.3%)	2 (14.3%) 12 (85.7%)	0
Healthcare worker, n (%)	No Yes	418 (87.4%) 60 (12.6%)	14 (100%) 0 (0%)	0
Close contact to high-risk person, n (%)	No Yes	358 (74.9%) 120 (25.1%)	8 (57.1%) 6 (42.9%)	0
Serious side effects to other vaccines, n (%)	No Yes	477 (99.8%) 1 (0.2%)	14 (100%) 0 (0%)	0
Severe immunosuppression, n (%)	No Yes	455 (95.2%) 23 (4.8%)	11 (78.6%) 3 (21.4%)	0
Acute fever, n (%)	No Yes	478 (100%) 0 (0%)	14 (100%) 0 (0%)	0
Pregnant, n (%)	No Yes	477 (99.8%) 1 (0.2%)	14 (100%) 0 (0%)	0
Recovered from COVID-19, n (%)	No Yes	472 (98.7%) 6 (1.3%)	14 (100%) 0 (0%)	0
Time vacc to 1st symptoms, median (IQR)	days	77 (47-119)	149 (122-234)	7.5
Time vacc/Delta outbreak to 1st symptoms, median (IQR)	days	49.5 (28.8-70)	78 (64-106.5)	49
Time vacc to 1st symptoms for Alpha & Delta patients vaccinated after Delta outbreak, median (IQR)	days	42 (24.8-58.8)	NA	84.1
Time vacc to positive test, median (IQR)	days	77 (47-120)	145 (103.3-210.3)	0.2
Time vacc/Delta outbreak	days	49 (29-71.3)	69 (51-107)	45.3

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

to positive test, median (IQR)				
Time vacc to positive test for Alpha & Delta patients vaccinated after Delta outbreak, median (IQR)	days	45 (25.5-60.5)	2 (2-2)	82.3
PCR ct value, median (IQR)		20.41 (17.8-26.17)	23.21 (22.47-25.77)	60.2
Severity of disease, n (%)	Asymptomatic Mild illness Moderate illness Severe illness Critical illness and death	24 (5%) 451 (94.4%) 1 (0.2%) 2 (0.4%) 0 (0%)	2 (14.3%) 1 (7.1%) 6 (42.9%) 3 (21.4%) 2 (14.3%)	0
Source of infection	Club, party, bar Cultural event Family Friends Holidays Hospital Religion Retirement and nursing home School Sports Unknown Work	17 (3.6%) 7 (1.5%) 132 (27.6%) 26 (5.4%) 106 (22.2%) 7 (1.5%) 3 (0.6%) 19 (4%) 9 (1.9%) 4 (0.8%) 112 (23.4%) 36 (7.5%)	0 (0%) 0 (0%) 3 (21.4%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 4 (28.6%) 0 (0%) 0 (0%) 7 (50%) 0 (0%)	0
Baseline risk factor				
Chronic lung disease	No Yes	446 (93.3%) 32 (6.7%)	12 (85.7%) 2 (14.3%)	0
Chronic renal disease	No Yes	473 (99%) 5 (1%)	11 (78.6%) 3 (21.4%)	0
Cancer	No Yes	465 (97.3%) 13 (2.7%)	12 (85.7%) 2 (14.3%)	0
Cardiac disease	No Yes	447 (93.5%) 31 (6.5%)	5 (35.7%) 9 (64.3%)	0
Arterial hypertension	No Yes	410 (86%) 67 (14%)	7 (50%) 7 (50%)	0.2
Diabetes	No Yes	441 (92.3%) 37 (7.7%)	10 (71.4%) 4 (28.6%)	0
Obesity	No Yes	476 (99.6%) 2 (0.4%)	13 (92.9%) 1 (7.1%)	0

Supplementary Table 5. Baseline characteristics of patients with breakthrough infection who showed asymptomatic or mild illness (n=478) compared to patients with moderate, severe and critical illness (n=478).

Variable	Level	asympto	mild	moderate	severe	critical/ death	% miss
n		26	452	7	5	2	
Age, med (IQR)	Years	67 (32.5-82.3)	43 (43-61.3)	77 (63-81)	81 (79-87)	87 (85-89)	0
Sex, n (%)	Man Woman	10 (38.5%) 16 (61.5%)	214 (47.3%) 238 (52.7%)	5 (71.4%) 2 (28.6%)	3 (60%) 2 (40%)	1 (50%) 1 (50%)	0
Type of vaccine, n (%)	Moderna Pfizer/BioNTech Janssen AstraZeneca	13 (50%) 13 (50%) 0 (0%) 0 (0%)	239 (52.9%) 209 (46.2%) 3 (0.7%) 1 (0.2%)	4 (57.1%) 3 (42.9%) 0 (0%) 0 (0%)	1 (20%) 4 (80%) 0 (0%) 0 (0%)	0 (0%) 2 (100%) 0 (0%) 0 (0%)	0
Variants	Alpha Delta	2 (25%) 6 (75%)	7 (2.8%) 244 (97.2%)	0 (0%) 5 (100%)	2 (50%) 2 (50%)	1 (50%) 1 (50%)	0
Indication for vaccination							
Chronic diseases, n (%)	No Yes	13 (50%) 13 (50%)	321 (71%) 131 (29%)	0 (0%) 7 (100%)	1 (20%) 4 (80%)	0 (0%) 2 (100%)	0
Healthcare worker, n (%)	No Yes	23 (88.5%) 3 (11.5%)	395 (87.4%) 57 (12.6%)	7 (100%) 0 (0%)	5 (100%) 0 (0%)	2 (100%) 0 (0%)	0
Close contact to high-risk person, n (%)	No Yes	14 (53.8%) 12 (46.2%)	344 (76.1%) 108 (23.9%)	5 (71.4%) 2 (28.6%)	3 (60%) 2 (40%)	0 (0%) 2 (100%)	0
Serious side effects to other vaccines, n (%)	No Yes	26 (100%) 0 (0%)	451 (99.8%) 1 (0.2%)	7 (100%) 0 (0%)	5 (100%) 0 (0%)	2 (100%) 0 (0%)	0
Severe immunosuppression, n (%)	No Yes	24 (92.3%) 2 (7.7%)	431 (95.4%) 21 (4.6%)	5 (71.4%) 2 (28.6%)	4 (80%) 1 (20%)	2 (100%) 0 (0%)	0
Acute fever, n (%)	No Yes	26 (100%) 0 (0%)	452 (100%) 0 (0%)	7 (100%) 0 (0%)	5 (100%) 0 (0%)	2 (100%) 0 (0%)	0
Pregnant, n (%)	No Yes	26 (100%) 0 (0%)	451 (99.8%) 1 (0.2%)	7 (100%) 0 (0%)	5 (100%) 0 (0%)	2 (100%) 0 (0%)	0
Recovered from COVID19, n (%)	No Yes	25 (96.2%) 1 (3.8%)	447 (98.9%) 5 (1.1%)	7 (100%) 0 (0%)	5 (100%) 0 (0%)	2 (100%) 0 (0%)	0

Time vacc to 1st symptoms, median (IQR)	days	148 (148-148)	77 (47-119)	191.5 (109.3-244.5)	123 (104-167.5)	122 (122-122)	7.5
Time vacc/Delta outbreak to 1st symptoms, median (IQR)	days	107 (107-107)	49 (28.5-69.5)	106.5 (98.3-108.3)	64 (63-65)	25 (25-25)	49
Time vacc to 1st symptoms for Alpha & Delta patients vaccinated after Delta outbreak, median (IQR)	days	NA	42 (24.8-58.8)	NA	NA	NA	84.1
Time vacc to positive test, median (IQR)	days	71.5 (41.3-135.3)	78 (48-120.5)	150 (96.5-242)	85 (2-123)	62 (32-92)	0.2
Time vacc/Delta outbreak to positive test, median (IQR)	days	36 (20.8-57.5)	49.5 (30.3-71.8)	107 (78-109)	32 (2-63.8)	13.5 (7.8-19.3)	45.3
Time vacc to positive test for Alpha & Delta patients vaccinated after Delta outbreak, median (IQR)	days	66.5 (44.3-88.8)	45.5 (27.3-60.5)	NA	2 (2-2)	2 (2-2)	82.3
PCR ct value, median (IQR)		28.8 (28.35-31.31)	20.27 (17.73-25.74)	25.03 (23.38-26.68)	NA	23.21 (23.21-23.21)	60-2
Hospitalisation	No Yes	24 (92.3%) 2 (7.7%)	451 (99.8%) 1 (0.2%)	1 (14.3%) 6 (85.7%)	2 (40%) 3 (60%)	0 (0%) 2 (100%)	0
Source of infection	Club, party, bar Cultural event Family Friends Holidays	1 (3.8%) 0 (0%) 5 (19.2%) 1 (3.8%) 4 (15.4%)	16 (3.5%) 7 (1.5%) 126 (27.9%) 25 (5.5%) 102 (22.6%)	0 (0%) 0 (0%) 4 (57.1%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)	0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)	0

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

	Hospital	0 (0%)	7 (1.5%)	0 (0%)	0 (0%)	0 (0%)	
	Religion	0 (0%)	3 (0.7%)	0 (0%)	0 (0%)	0 (0%)	
	Retirement and nursing home	8 (30.8%)	11 (2.4%)	1 (14.3%)	2 (40%)	1 (50%)	
	School	0 (0%)	9 (2%)	0 (0%)	0 (0%)	0 (0%)	
	Sports	0 (0%)	4 (0.9%)	0 (0%)	0 (0%)	0 (0%)	
	Unknown	7 (26.9%)	106 (23.5%)	2 (28.6%)	3 (60%)	1 (50%)	
	Work	0 (0%)	36 (8%)	0 (0%)	0 (0%)	0 (0%)	
Baseline risk factor							
Chronic lung disease	No	20 (76.9%)	426 (94.2%)	6 (85.7%)	4 (80%)	2 (100%)	0
	Yes	6 (23.1%)	26 (5.8%)	1 (14.3%)	1 (20%)	0 (0%)	
Chronic renal disease	No	26 (100%)	447 (98.9%)	5 (71.4%)	5 (100%)	1 (50%)	0
	Yes	0 (0%)	5 (1.1%)	2 (28.6%)	0 (0%)	1 (50%)	
Cancer	No	25 (96.2%)	440 (97.3%)	6 (85.7%)	4 (80%)	2 (100%)	0
	Yes	1 (3.8%)	12 (2.7%)	1 (14.3%)	1 (20%)	0 (0%)	
Cardiac disease	No	23 (88.5%)	426 (94.2%)	2 (28.6%)	1 (20%)	0 (0%)	0
	Yes	3 (11.5%)	26 (5.8%)	5 (71.4%)	4 (80%)	2 (100%)	
Arterial hypertension	No	22 (84.6%)	388 (86%)	4 (57.1%)	3 (60%)	0 (0%)	0
	Yes	4 (15.4%)	63 (14%)	3 (42.9%)	2 (40%)	2 (100%)	
Diabetes	No	25 (96.2%)	416 (92%)	4 (57.1%)	4 (80%)	2 (100%)	0
	Yes	1 (3.8%)	36 (8%)	3 (42.9%)	1 (20%)	0 (0%)	
Obesity	No	26 (100%)	450 (99.6%)	6 (85.7%)	5 (100%)	2 (100%)	0
	Yes	0 (0%)	2 (0.4%)	1 (14.3%)	0 (0%)	0 (0%)	

Supplementary Table 6. Chronic diseases and conditions leading to an especially high risk for severe course of disease according to the Federal Office of Public Health. According to the FOPH, only adults are considered to be at high risk. Therefore, the following criteria refer only to adults.

Condition	Specific disease	Details
Adults with Trisomy 21		
Hypertension	Arterial hypertension with end-organ damage	
	Therapy-resistant arterial hypertension	
Cardiovascular disease	General	NYHA II-IV and NT-proBNP > 125 pg/ml
		2 cardio-vascular risk factors
		Prior stroke and/or symptomatic vasculopathy
		Chronic renal insufficiency (Stage 3, GFR <60 ml/min)
	Coronary heart disease	Myocardial infarction in the past 12 months
		Symptomatic chronic coronary syndrome despite medical treatment
	Disease of the heart valves	Moderate or serious stenosis and/or regurgitation in addition to meeting at least one general criterion
		Any surgical or percutaneous valve replacement in addition to meeting at least one general criterion
	Cardiac insufficiency	Patients with dyspnea of functional class NYHA II–IV or NT-proBNP > 125pg/ml despite medical treatment for any LVEF (HFpEF, HFmrEF, HFrEF)
		Cardiomyopathy with any cause
		Pulmonary arterial hypertension
	Arrhythmia	Auricular fibrillation with a CHA2DS2-VASc score of at least 2 points

		Prior implant of pacemaker (incl. ICD and/or CRT implantation) in addition to meeting one general criterion
	Adults with congenital heart disease	Congenital heart disease according to the individual assessment of the attending cardiologist
Diabetes	Diabetes mellitus, with long-term complications or a HbA1c of $\geq 8\%$	
Chronic pulmonary and respiratory disease	Chronic obstructive lung diseases GOLD Grade II-IV	
	Pulmonary emphysema	
	Uncontrolled asthma, in particular serious bronchial asthma	
	Interstitial lung diseases / pulmonary fibrosis	
	Active lung cancer	
	Pulmonary arterial hypertension	
	Pulmonary vascular disease	
	Active Sarcoidosis	
	Cystic fibrosis	
	Chronic lung infections (atypical mycobacteriosis, bronchiectasis, etc.)	
	Ventilated patients	
Diseases/Therapies that weaken the immune system	Diseases with severely reduced lung capacity	
	Serious immunosuppression (e.g. HIV-infection with a CD4+ T cell number of $< 200/\mu\text{l}$)	
	Neutropenia ($< 1'000$ neutrophils/ μl) for ≥ 1 week	
	Lymphocytopenia (< 200 lymphocytes/ μl)	
	Hereditary immunodeficiencies	

	Use of medication that suppresses the immune defenses (such as long-term use of glucocorticoids (prednisolone equivalent > 20 mg/day), monoclonal antibodies, cytostatics, biologics etc.)	
	Aggressive lymphomas (all entities)	
	Acute lymphatic leukaemia	
	Acute myeloid leukaemia	
	Acute promyelocytic leukaemia	
	T-cell prolymphocytic leukaemia	
	Primary lymphomas of the central nervous system	
	Stem cell transplantation	
	Amyloidosis (light-chain (AL) amyloidosis)	
	Chronic lymphatic leukaemia	
	Multiple myeloma	
	Sickle-cell disease	
	Bone marrow transplant	
	Solid organ transplant	
	Individuals on a transplant waiting list	
Cancer	Cancer undergoing medical treatment	
Obesity	Patients with a body-mass index (BMI) of 35 kg/m ² or more	
Liver disease	Cirrhosis of the liver	
Renal disease	Chronic renal insufficiency with a GFR < 60 ml/min	

Supplementary Table 7. Multivariable logistic regression exploring the relationships between potential risk factors and the probability to suffer from a SARS-CoV-2 breakthrough infection using the 'control' group 2. Confidence intervals and p-values are computed using Firth penalization, because the level "Yes" for "Acute fever" was rarely observed. Only Moderna and Pfizer/BioNTech vaccines are compared, because no other vaccine was used in the control population.

	n	Odds ratio	CI	p
Intercept	107039	0.010	(0.008-0.013)	<0.001
Age		0.982	(0.977-0.987)	<0.001
Gender (woman vs. man)		1.048	(0.876-1.255)	0.606
Vaccine (Pfizer/BioNTech, ref =Moderna)		1.530	(1.342-1.743)	<0.001
Chronic disease (=Yes)		1.990	(1.590-2.482)	<0.001
Healthcare worker (=Yes)		1.927	(1.438-2.538)	<0.001
Close contact with high-risk person (=Yes)		0.934	(0.752-1.153)	0.530
Pregnant (=Yes)		1.265	(0.144-4.581)	0.784
Severe immunosuppression (=Yes)		1.248	(0.806-1.849)	0.307
Serious side-effects from previous vaccines (=Yes)		0.289	(0.033-1.035)	0.058
Acute fever (=Yes)		2.693	(0.021-19.002)	0.549
Recovered from COVID-19 (=Yes)		0.431	(0.178-0.861)	0.014

Supplementary Table 8. Multivariable logistic regression exploring the relationships between potential risk factors and the probability to suffer from a Delta variant caused breakthrough infection using the 'control' set 1. Only Moderna and Pfizer/BioNTech vaccines are compared, because no other vaccine was used in the control population.

	n	Odds ratio	CI	p
Intercept	125076	0.004	(0.003-0.006)	<0.001
Age		0.985	(0.978-0.991)	<0.001
Gender (woman vs. man)		0.998	(0.779-1.280)	0.988
Vaccine (Pfizer/BioNTech, ref =Moderna)		1.473	(1.232-1.759)	<0.001
Chronic disease (=Yes)		1.972	(1.444-2.674)	<0.001
Healthcare worker (=Yes)		1.576	(1.061-2.278)	0.019
Close contact with high-risk person (=Yes)		0.918	(0.677-1.231)	0.575
Pregnant (=Yes)		1.247	(0.071-5.614)	0.826
Recovered from COVID19 (=Yes)		0.18	(0.030-0.561)	0.016

Supplementary Table 9. Multivariable logistic regression exploring the relationships between potential risk factors and the probability to suffer from a Delta variant caused breakthrough infection using the 'control' set 2. Only Moderna and Pfizer/BioNTech vaccines are compared, because no other vaccine was used in the control population.

	n	Odds ratio	CI	p
Intercept	106807	0.006	(0.004-0.009)	<0.001
Age		0.979	(0.972-0.986)	<0.001
Gender (woman vs. man)		1.008	(0.787-1.293)	0.947
Vaccine (Pfizer/BioNTech, ref =Moderna)		1.551	(1.296-1.856)	<0.001
Chronic disease (=Yes)		1.885	(1.374-2.568)	<0.001
Healthcare worker (=Yes)		2.184	(1.484-3.126)	<0.001
Close contact with high-risk person (=Yes)		0.957	(0.708-1.278)	0.768
Pregnant (=Yes)		2.331	(0.264-8.516)	0.367
Recovered from COVID-19 (=Yes)		0.301	(0.063-0.851)	0.020

Supplementary Table 10. Multivariable generalized linear model with binomial distribution investigating the probability of suffering from a breakthrough infection caused by the Delta variant (as compared to the Alpha variant taken as the reference) as a function of individual characteristics. Confidence intervals and p-values are computed using Firth penalization due to rare or no observations in some factors' levels.

	n	Odds ratio	CI	p
Intercept	270	977.34	(26.01-310113.57)	<0.001
Age		0.93	(0.85-0.98)	0.007
Gender (woman vs. man)		1.05	(0.21-5.39)	0.951
Vaccine Pfizer/BioNTech, (ref=Moderna)		0.01	(0.00-0.86)	0.044
Vaccine Janssen, (ref=Moderna)		2.06	(0.06-62.71)	0.663
Vaccine AstraZeneca (ref=Moderna)		2.14	(0.06-30.62)	0.602
Healthcare worker (=Yes)		3.55	(0.11-843.96)	0.516
Close contact with high-risk person (=Yes)		0.62	(0.13-2.90)	0.534
Severe immunosuppression (=Yes)		0.79	0.05-14.70	0.868
Pregnant (=Yes)		0.01	(0.00-4.15)	0.116
Chronic disease (=Yes)		0.12	0.01-1.20	0.071
Chronic lung disease (=Yes)		1.37	0.18-22.72	0.780
Chronic renal disease (=Yes)		0.48	0.02-12.17	0.641
Cancer (=Yes)		0.33	0.01-5.07	0.430
Cardiac disease (=Yes)		0.69	0.10-5.12	0.706
Arterial hypertension (=Yes)		6.93	1.26-57.33	0.025
Diabetes (=Yes)		3.09	0.43-35.82	0.278
Obesity (=Yes)		0.05	(0.00-1.16)	0.061

Supplementary Material.

Geographical setting. The City of Basel shows a population density of 7451.6/km², a population density comparable to San Francisco (7'262.12/km²) (U.S. Census Bureau QuickFacts: San Francisco County, California) and Milan (7'681.42 ab./km²) (Demo-Geodemo. - Mappe, Popolazione, Statistiche Demografiche dell'ISTAT).

Vaccine availability. In the beginning (January to April 2021) only elderly people above the age of 75, individuals at high risk for worse outcomes, and healthcare professionals could get vaccinated. From May 2021 onwards all Swiss citizens above the age of 16, and starting at the end of June 2021 all individuals above the age of 12 could get the vaccination. The BNT162b2 mRNA vaccine (Pfizer/BioNTech) was the first COVID-19 vaccine approved by the Swiss Agency for Therapeutic Products (Swissmedic) and therefore the only vaccine administered in December 2020. In January 2021 mRNA-1273 (Moderna) received the approval, followed by Ad26.COV2.S (Janssen) in March 2021. However, due to the missing pre-purchase of Ad26.COV2.S, the vaccine could not be administered until October 2021.

References

1. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med* 2021; **384**(5): 403-16.
2. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. *N Engl J Med* 2021; **384**(15): 1412-23.
3. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* 2020; **383**(27): 2603-15.
4. Stephenson KE, Le Gars M, Sadoff J, et al. Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. *JAMA* 2021; **325**(15): 1535-44.
5. Bergwerk M, Gonen T, Lustig Y, et al. Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. *N Engl J Med* 2021; **385**(16): 1474-84.
6. Tenforde MW, Self WH, Adams K, et al. Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. *JAMA* 2021; **326**(20): 2043-54.
7. Thompson MG, Burgess JL, Naleway AL, et al. Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. *N Engl J Med* 2021; **385**(4): 320-9.
8. Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. *N Engl J Med* 2021; **385**(24): e83.
9. Chodick G, Tene L, Rotem RS, et al. The effectiveness of the TWO-DOSE BNT162b2 vaccine: analysis of real-world data. *Clin Infect Dis* 2021.
10. Thompson MG, Stenehjem E, Grannis S, et al. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings. *N Engl J Med* 2021; **385**(15): 1355-71.
11. Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. *Lancet* 2021; **397**(10287): 1819-29.
12. Hacisuleyman E, Hale C, Saito Y, et al. Vaccine Breakthrough Infections with SARS-CoV-2 Variants. *N Engl J Med* 2021; **384**(23): 2212-8.
13. Thomas SJ, Moreira ED, Jr., Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. *N Engl J Med* 2021; **385**(19): 1761-73.
14. Lipsitch M, Krammer F, Regev-Yochay G, Lustig Y, Balicer RD. SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. *Nat Rev Immunol* 2021.
15. Liu C, Lee J, Ta C, et al. A Retrospective Analysis of COVID-19 mRNA Vaccine Breakthrough Infections - Risk Factors and Vaccine Effectiveness. *medRxiv* 2021.
16. Aslam S, Adler E, Mekeel K, Little SJ. Clinical effectiveness of COVID-19 vaccination in solid organ transplant recipients. *Transpl Infect Dis* 2021; **23**(5): e13705.
17. Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, et al. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. *Clin Microbiol Infect* 2021; **27**(11): 1652-7.
18. Qin CX, Moore LW, Anjan S, et al. Risk of Breakthrough SARS-CoV-2 Infections in Adult Transplant Recipients. *Transplantation* 2021; **105**(11): e265-e6.
19. Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. *Lancet* 2021; **398**(10316): 2093-100.
20. Mizrahi B, Lotan R, Kalkstein N, et al. Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine. *Nat Commun* 2021; **12**(1): 6379.
21. Organization WH. Interim statement on booster doses for COVID-19 vaccination. 04.10.2021 2021. <https://www.who.int/news/item/04-10-2021-interim-statement-on-booster-doses-for-covid-19-vaccination> (accessed 23.12.2021 2021).
22. Vilches TN, Shoukat A, Ferreira CP, Moghadas SM. Projecting influenza vaccine effectiveness: A simulation study. *PLoS One* 2020; **15**(11): e0241549.
23. Mlcochova P, Kemp SA, Dhar MS, et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. *Nature* 2021; **599**(7883): 114-9.

24. Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. *Nature* 2021; **596**(7871): 276-80.
25. Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. *Nat Rev Mol Cell Biol* 2022; **23**(1): 3-20.
26. Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. *Nature* 2020; **581**(7807): 215-20.
27. Li J, Lai S, Gao GF, Shi W. The emergence, genomic diversity and global spread of SARS-CoV-2. *Nature* 2021; **600**(7889): 408-18.
28. McCallum M, Walls AC, Sprouse KR, et al. Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants. *Science* 2021: eabl8506.
29. Puranik A, Lenehan PJ, Silvert E, et al. Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. *medRxiv* 2021.
30. Burki TK. Omicron variant and booster COVID-19 vaccines. *Lancet Respir Med* 2021.
31. Lu L, Mok BW, Chen LL, et al. Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients. *Clin Infect Dis* 2021.
32. Office FS. Sustainable development, regional and international disparities, statistical basis and overviews: Federal Statistical Office, 2021.
33. Bureau USC. Boston City, Massachusetts. 2021. <https://www.census.gov/quickfacts/fact/table/bostoncitymassachusetts/POP010220> (accessed 23.12.2021 2021).
34. Park N. Estimates of the population for the UK, England and Wales, Scotland and Northern Ireland. 25.06.2021 2021. <https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/populationestimatesforukenglandandwalesscotlandandnorthernireland> (accessed 23.12.2021 2021).
35. Madrid Co. El municipio en cifras. 2021. <http://portalestadistico.com/municipioencifras/?pn=madrid&pc=ZTV21> (accessed 23.12.2021 2021).
36. Statistisches Amt BS. Bestand und Struktur. 2021. <https://www.statistik.bs.ch/zahlen/tabellen/1-bevoelkerung/bestand-struktur.html> (accessed 23.12.2021 2021).
37. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Bethesda (MD); 2021.
38. Stange M, Mari A, Roloff T, et al. SARS-CoV-2 outbreak in a tri-national urban area is dominated by a B.1 lineage variant linked to a mass gathering event. *PLoS Pathog* 2021; **17**(3): e1009374.
39. Wegner F, Roloff T, Huber M, et al. External quality assessment of SARS-CoV-2-sequencing: An ESGMD-SSM pilot trial across 15 European laboratories. *J Clin Microbiol* 2021: JCM0169821.
40. Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. *Lancet Infect Dis* 2021.
41. Day M. Covid-19: Stronger warnings are needed to curb socialising after vaccination, say doctors. *BMJ* 2021; **372**: n783.
42. Kojima N, Klausner JD. Protective immunity after recovery from SARS-CoV-2 infection. *Lancet Infect Dis* 2021.
43. Townsend JP, Hassler HB, Wang Z, et al. The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study. *Lancet Microbe* 2021; **2**(12): e666-e75.
44. Crotty S. Hybrid immunity. *Science* 2021; **372**(6549): 1392-3.
45. Klompas M. Understanding Breakthrough Infections Following mRNA SARS-CoV-2 Vaccination. *JAMA* 2021; **326**(20): 2018-20.
46. Stefan N. Metabolic disorders, COVID-19 and vaccine-breakthrough infections. *Nat Rev Endocrinol* 2021.
47. Wang SY, Juthani PV, Borges KA, et al. Severe breakthrough COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era. *Lancet Microbe* 2021.





